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Membranous nephropathy in 52 hepatitis B surface antigen (HBsAg)
carrier children in Taiwan. To elucidate the prognosis and the causative
viral antigens of hepatitis B virus (HBV)-associated childhood membra-
nous nephropathy (MN), the clinical course and glomerular HBV
antigens were studied in 52 HB5Ag carrier children with MN (40 boys,
12 girls). With Fab fragments of monoclonal antibodies, hepatitis B e
antigen (HBeAg) was detected in the glomerular deposits in 41(95%) of
43 cases but HBsAg and hepatitis B core antigen (HBcAg) in none.
HBeAg was detected in sera from 43 (93%) of 46 children examined.
These results suggest that HBeAg plays an important role in the
development of MN in HBsAg carrier children. During the follow-up
period (mean, 4 years), complete remission was found in 64% and 92%
of the patients followed for one and seven years, respectively; only one
child had mild renal function impairment. These findings suggest a
favorable outcome of HBsAg-associated childhood MN. The patient's
age, disease duration, amount of glomerular deposit, focal sclerosis and
disease stage appeared to affect the clinical course. HB5Ag serocon-
version to HBsAg-negative occurred in seven cases, and all (100%) had
quick remission in two years. In patients with persistent HBsAg
carriage, serum HBeAg status alone did not correlate with remission
rate and remission occurred usually before the HBeAg seroconversion
to anti-HBe. These findings, together with the predominant horizontal
infection in these children in contrast to the frequent vertical (perinatal)
transmission from HB5Ag carrier mothers in HBsAg carriers in Taiwan,
suggest that factors other than HBeAg per se may also play important
roles.
Since the association of hepatitis B surface antigen (HBsAg)
with membranous nephropathy (MN) was demonstrated by
Combes et al [1], hepatitis B virus (HBV) has been related to
several types of glomerulonephritis [2—111, mostly MN [4—111.
This association is particularly striking in children and has been
reported in countries with high or low prevalence of HBV
infection. However, the nature of the antigen(s) involved and
the clinical course of the HBV-associated childhood MN have
not been clarified. All three major HBV-related antigens, that
is, HBsAg, hepatitis B e antigen (HBeAg), and hepatitis B core
antigen (HBcAg) have been implicated: HBcAg and/or HBsAg
in Poland [5, 11], and HBeAg in Japan [4, 12, 13]. HBeAg exists
in serum in two forms: free or complexed with immunoglobulin
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[12]. Ito et al found that two patients who recovered from
previous massive proteinuria were HBeAg-negative and anti-
HBe-positive, and suggested that patients with HBeAg-medi-
ated MN might remit as they seroconverted from HBeAg to
anti-HBe [13]. However, the exact time relationship between
HBeAg seroconversion and remission is not known.
Our study in Taiwan [7] failed to demonstrate the glomerular
deposition of HBsAg in the majority of cases, and the role of
HBcAg and HBeAg could not be determined because of the
lack of appropriate antibody reagents [7]. Since then, case
numbers have quadrupled and, with the availability of the Fab
fragments of mouse monoclonal antibodies to HBsAg (anti-
HBs), HBcAg (anti-HBc) and HBeAg (anti-HBe), we are now
able to specifically determine the antigen(s) involved. More-
over, longer follow-up of the earlier cases also allowed a better
understanding of the patients' outcome, in relation to the serum
HBeAglanti-HBe status.
Methods
Patients
In the renal biopsy series examined during January 1976 to
March 1988 at the Department of Pathology, National Taiwan
University Hospital, 463 were children with primary glomerular
disease and under 17 years of age; 54 children (11.7%) had MN.
Of these, 52 children (96.3%) with MN were positive for serum
HBsAg and formed the basis of this study; 13 cases have been
previously reported [7].
Morphologic and immunohistologic studies
Percutaneous kidney biopsies were divided into three parts
for light microscopic, immunofluorescence and electron micro-
scopic studies [71.
Detection of HBV antigens
Glomerular deposits were stained for HBsAg and HBcAg
with polyclonal rabbit anti-HBs (Behringer, Marburg, FRG)
and anti-HBc (Dakopatts, Santa Barbara, California, USA),
respectively, followed by FITC-labeled goat anti-rabbit anti-
sera. However, both gave false positive results in a few of MN
without serum HBsAg, and the anti-HBc cross reacted with
HBeAg in radioimmunoassay. Both were therefore used only
for screening purposes.
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Glomerular deposits of HBV-related antigens were tested
further by direct immunofluorescence technique using FITC-
labeled mouse monoclonal anti-HBs/a Fab' (IgG3), anti-HBc/b
F(ab')2 (IgG2), and anti-HBe Fab (an 1:1 mixture of anti-
HBe/a, IgG2 and anti-HBe/b, IgG1). These reagents were
supplied by Y. Miyakawa and later obtained from the Institute
of Immunology Co., Ltd, Tokyo, Japan; the individual deter-
minants on HBsAg, HBcAg and HBeAg, to which the mono-
clonal antibodies are directed, have been characterized [14, 15].
For those cases without frozen tissue available for examina-
tion, the HBV antigens were examined in the deparaffinized
sections by peroxidase-anti-peroxidase complex (PAP) tech-
nique [161 using the FITC-labeled monoclonal antibodies de-
scribed above, followed by rabbit anti-mouse immunoglobulins
(Cappel, West Chester, Pennsylvania, USA) or F(ab')2 of rabbit
antimouse IgG (Zymed Lab, San Francisco, California, USA).
Contfols
To test the specificity of the FITC-labeled mouse monoclonal
antibodies, six cryostat liver sections known to be positive for
HBsAg were selected, including four positive also for nuclear
andlor cytoplasmic HBcAg. The FITC-labeled .anti-HBs stained
HBsAg in all six specimens, and the anti-HBc stained HBcAg in
the four cases positive for liver HBcAg. HBeAg was detected in
none.
Negative controls included 24 cases of MN (22 adults and 2
children) and two children with mesangiocapillary glomerulo-
nephritis (MCGN; including one with rheumatoid factor in
serum), and all were negative for serum HBsAg. Five adults of
MN who were positive for HBsAg but negative for HBeAg
were also examined. Using Fab fragments of the monoclonal
primary and secondary antibodies, glomerular HBeAg or other
HBV antigens were detected in none of both groups by the
direct immunofluorescent stain on frozen cryostat sections
and/or by the indirect PAP stain on deparaffinized section. The
positive control group included three adults with HBsAg and
HBeAg in serum; all had glomerular deposition of HBeAg and
one also had trace amount of HBsAg, but none had HBcAg.
Serologic tests
Serum HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc
were measured by radioimmunoassay (Abbott Laboratories,
North Chicago, Illinois, USA).
Statistics
Fisher's exact test was used for statistical analysis.
Results
Clinical features
The ages of the 52 HBsAg-positive children with MN (40
boys and 12 girls) ranged from 2 to 16 years (mean sr, 7.6
3.6 years), with a peak age of disease onset between two and
five years (mean SD, 5.9 3.1 years; Fig. 1). The disease
duration before biopsy varied from 6 days to 10 years (mean
SD, 20.2 26.5 months). Nephrotic syndrome (NS) occurred
during the course in 43 (83.3%), while seven had proteinuria
alone and two, hematuria alone.
Serum ilBeAg was detected in 43 (93%) of 46 patients.
Serologic study was also performed in 47 patients followed.
Age of onset (year)
Fig. 1. Distribution of onset age in 52 children with HBV-related
,ne,nbranous nephropathy. Symbols are: (D) male, 40; (D) female, 12.
Fig. 2. Granular deposition of HBeAg along the glomerulur capillary
walls, Direct immunofluorescence stain for HBeAg with Fab fragments
of mouse monoclonal anti-Hile, x720.
HBsAg was found in 3(8.6%) of 35 mothers, and 14(33%) of 43
siblings.
Pathologic features
The stages of glomerular changes according to the classifica-
tion of Ehrenreich and Churg [17] were: I (4 cases), I-Il (19
cases), 11(16 cases), lI-Ill (10 cases), III (3 cases), and IV
(none). Focal glomerular sclerosis was found in 20%.
Detection of HBV antigens
HBeAg was detected in the glomerular deposits in all 26 cases
examined by direct immunofluorescence (Fig. 2), but HBcAg
and HBsAg in none. HBeAg, but not HBsAg or HBcAg, was
also detected in deparaffinized section by indirect PAP tech-
nique in 15 of additional 17 cases (Fig. 3). HBeAg was detected
in the second biopsies in two cases who remained positive for
serum HBeAg, but not in one child who had cleared serum
HBeAg.
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Fig. 3. Peroxidase-anti-peroxidase complex (PAP) stain for HBeAg.
Fab fragments of mouse monoclonal anti-HBe and polyclonal rabbit
anti-mouse antibodies were used to stain HBeAg in deparaffinized
kidney section (2 thick) from a child with membranous nephropathy
who had HBsAg and HBeAg in the serum. x600.
Follow-up study
All the patients had been followed for 2 to 145 months (mean
SD, 47.56 35.45 months); 38 (73%) had received pred-
nisolone therapy, but most did not respond. Adenine arabino-
side (Ara-A) and thymic extract (thymostimulin, Serono Co.,
Italy) had been given to 10 cases. Four children did not receive
any special therapy and all remitted in two years. The clinical
course was analyzed among 49 children followed for a minimum
of 12 months, the cumulative remission rate of the disease was
high in seven years, and most patients remitted in two years
(Table 1). At the last visit up to 12 years after renal biopsy, none
had renal failure and only one had a mild elevation of serum
creatinine (1.5 mgldl). Two were recent cases and one lost to
follow-up. The 14 patients who did not remit had mild protein-
uria and/or microhematuria but none had NS.
Correlation of clinical parameters with disease course
The cumulative remission rate did not differ in relation to sex
or age, but children of younger age or with a shorter disease
duration remitted earlier (Table 1). During the course, seven
children lost HBsAg and HBeAg, 12 became HBeAg-negative
but HBsAg-positive, and 28 remained positive for both anti-
gens. All seven children who became HBsAg-negative remitted
in two years, significantly more frequent and earlier than those
who remained positive for serum HBeAg (Table 1). Serum
HBeAg alone did not correlate with remission and remission
occurred in 12 of 13 children before they lost HBeAg; but 12
(75%) of 16 cases who did not remit remained positive for serum
HBeAg.
Correlation of glomerular changes with outcome
The disease remitted earlier in patients with earlier disease
stage, smaller amount of deposits or absence of focal sclerosis
in glomeruli (Table 1).
Table 1. Annual remission rates in relation to clinical and pathologic
features in children with membranous nephropathy
Complete remission %
2-yr 5-yr 7-yr
Total 30/47 (64) 34/4 1 (83) 35/38 (92)
Age at biopsy
<6 yr 14/17 (82)" 14/16 (88) 14/14 (100)
>6 yr 16/30 (53)b 20/25 (80) 21/24 (91)d
Disease duration
<12 months 21/28 (75)C 22/27 (82) 23/24 (96)
>12 months 9/19 ((47)C 12/14 (86) 12/14 (86)
HB5Ag and/or HBeAg seroconversiona
HB5Ag(—) 7/7 (100) 7/7 (100) 7/7 (100)
HBeAg(—) 9/14 (64) 10/13 (77) 10/12 (83)
HBeAg(+) 13/24 (54) 15/19 (79) 16/17 (94)
Histologic stage
<I—lI 16/20 (80) 18/19 (95) 18/18 (100)
II 10/15 (67yJ 12/15 (80) 12/13 (92)
>11—Ill 4/12 (33)d 4/7 (57) 5/7 (71)
Subepithelial deposits
1 9/10 (90)" 9/9 (100) 9/9 (100)
2—4 17/33 (52)" 2 1/28 (75) 22/25 (88)
a HBsAg(—), HBsAg- and HBeAg-negative; HBeAg(—), HBsAg-
positive and HBeAg-negative; HBeAg(+), HB5Ag- and HBeAg-posi-
tive. P values are: b <0.05; C 0,0523; d <0.02.
Discussion
In this series, 52 (96.8%) of 54 children with MN were HBsAg
carriers, confirming that HBV infection is one major cause of
childhood MN in many countries [2, 4, 5, 7, 10, 11]. Although
the association of HBV infection and childhood MN is well
established, the causative antigen is not clear yet. HBsAg has
been detected by some investigators using polyclonal anti-HBs
[1—3, 5, 11, 18—21], but not by others [4, 6, 10, 221, and the
reliability of these observations has been seriously challenged
by Maggiore et al [23]. False positivity of HBV-related antigens
in the glomerulus was also encountered with direct or indirect
immunofluorescence stain using the whole immunoglobulins of
the antibodies, as noticed by Maggiore et a! [23]. This nonspe-
cific staining was obviated by using the Fab fragments of all the
antibodies. The current study could detect HBeAg in glomeru-
lar deposits in 41(95%) of 43 patients examined, but HBcAg
and HBsAg in none. It is also noticed that none of the patients
experienced relapse of nephrotic syndrome after they lost
serum HBeAg. These findings suggest that HBeAg plays an
important role in the pathogenesis of MN, as noticed by other
investigators [4, 12, 13]. This suggestion is supported by the
appropriate molecular size of HBeAg. In free form, HBeAg
measures 19,000 daltons; when complexed with immunoglobu-
lin, it meaures about 300,000 daltons [12]. In contrast, HBsAg is
larger than 3 million daltons even without antibody, and HBcAg
is not detected in serum. In experimental glomerulonephritis,
immune complexes of 1 million daltons or less could precipitate
in the glomerulus to induce typical MN [24]. Therefore, HBeAg
appeared to be the most appropriate antigen for the develop-
ment of HBV-associated MN.
Serum HBeAg positivity is high in children with MN in the
present series (93%) and that (93%, or 14/15) from South Africa
[101, but lower (19/31, or 61.3%) in Japan [13, 25, 26], and none
in Zimbabwe [19]. The reasons for this wide range of HBeAg
positivity are unknown, but may be related to the course of the
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disease and the time when HBV markers were examined, Some
children who had prolonged proteinuria, even after HBeAg
seroconversion, were more often associated with more ad-
vanced and even permanent glomerular damage.
Children with idiopathic MN have a better prognosis than
adults with MN [27, 28], but progression to renal failure is
encountered in 10% of the children of Habib, Kleinknecht and
Gubler [27] and in 27.3% in the series of Ramirez et al [29]. The
current study with a mean follow-up period of four years
demonstrated that HBV-related childhood MN had a cumula-
tive remission rate of 92% in seven years, with only one patient
showing mild renal function impairment. Except for one Afri-
can [22] and one American child [8], renal failure has not been
observed in children with HBV-related MN. The disease could
remit spontaneously in the majority of cases, as reported by
others [6, 10, 13, 22]. These findings suggest that HBV-associ-
ated MN in children runs a favorable course worldwide, even
better than the idiopathic MN. However, prolonged course and
permanent renal damage also exist. Little is known about the
natural course of the disease. We found that several clinical,
pathologic and virologic parameters were related to the disease
course. Remission occurred more often and significantly earlier
in children of younger age, with a shorter disease course, with
smaller amount of glomerular deposits, and without focal gb-
merular sclerosis. The significantly longer course and lower
remission rate in children with more advanced disease (stages
11-111 and HI) and/or focal sclerosis suggest that permanent
glomerular damage had already occurred in children with
prolonged persistent proteinuria, as also noticed by Wyszynska
et al [11]. HBeAg seroconversion to anti-HBe was frequently
accompanied by remission, as noticed by the other investiga-
tors [13]. However, remission usually occurred before HBeAg
seroconversion to anti-HBe, and even in the presence of serum
HBeAg. Furthermore, we found that remission was related
more closely to the HBsAg seroconversion; all the patients
(100%) with HBsAg seroconversion to HBsAg-negative and
anti-HB s-positive had remission in two years. These findings
indicate that circulating HBeAg may be required for the main-
tenance of the immunopathologic process in the kidney [13], but
its presence does not exclude the occurrence of a complete
remission [10]. The reason for this discrepancy is not clear.
The present study reveals that HBsAg carrier children with
MN are infected through the horizontal route; the predominant
horizontal HBV infection in children with MN in a country
where vertical transmission from HBsAg carrier mothers in the
perinatal period is prevalent [30] is striking. Our results suggest
that factors other than HBeAg per se, such as the patient's age,
the route of infection, the capability of host immune response
and the nature of the antibodies, particularly the anti-HBe, may
also play important roles in the pathogenesis and course of
HBV-related childhood MN.
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